Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 174, Issue -, Pages 265-276Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.04.050
Keywords
Celastrol; Ferulic acid; Apoptosis; Anti-tumor; Hybridization
Categories
Funding
- Academic Innovation Project of Jiangsu Department of Education [1150021667]
- Double First Class Subject Innovation Team Construction Project of China Pharmaceutical University [CPU2018GY12]
Ask authors/readers for more resources
On the basis of the hybridization strategy of natural products, a total of 32 novel celastrol hybrids were designed, synthesized and evaluated for their antitumor activities. Most of these derivatives exihibited significant antiproliferative activities compared to celastrol, among which compound 29 displayed the strongest inhibitory capability [IC50 = 0.15 +/- 0.03 mu M (A549),0.17 +/- 0.03 mu M (MCF-7), 0.26 +/- 0.02 mu M (HepG2)], which exhibited equal or superior anti-cancer activities in comparison to 2-cyano-3,12-dioxoolean-1,9 (11)-dien-28-oic acid methyl ester (CDDO-Me). The mechanism of pharmacological research indicated that 29 possessed the ability to disrupt Hsp90-Cdc37 complex which was stronger than celastrol. Meanwhile, compound 29 could induce abnormal regulation of clients (p-Akt and Cdk4) of Hsp90 and cell cycle arrest at G(0)/G(1) phase in a concentration-dependent manner. In addition, compound 29 could also induce cell apoptosis through the death receptor pathway on A549 cells. Taken together, our results demonstrated that 29 might be a promising novel candidate for further druggability research. (C) 2019 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available